PE20170296A1 - Procedimiento para fabricar un producto de acetato de glatiramer - Google Patents
Procedimiento para fabricar un producto de acetato de glatiramerInfo
- Publication number
- PE20170296A1 PE20170296A1 PE2016001955A PE2016001955A PE20170296A1 PE 20170296 A1 PE20170296 A1 PE 20170296A1 PE 2016001955 A PE2016001955 A PE 2016001955A PE 2016001955 A PE2016001955 A PE 2016001955A PE 20170296 A1 PE20170296 A1 PE 20170296A1
- Authority
- PE
- Peru
- Prior art keywords
- glatiramer acetate
- mannitol
- procedure
- manufacturing
- acetate product
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 4
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 4
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 3
- 229930195725 Mannitol Natural products 0.000 abstract 3
- 235000010355 mannitol Nutrition 0.000 abstract 3
- 239000000594 mannitol Substances 0.000 abstract 3
- 239000000706 filtrate Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 239000003186 pharmaceutical solution Substances 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229940071643 prefilled syringe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170296A1 true PE20170296A1 (es) | 2017-04-14 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001955A PE20170296A1 (es) | 2015-01-28 | 2015-09-21 | Procedimiento para fabricar un producto de acetato de glatiramer |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (enExample) |
| EP (3) | EP3113785A4 (enExample) |
| JP (2) | JP2018503627A (enExample) |
| KR (2) | KR101737295B1 (enExample) |
| CN (1) | CN107530394B (enExample) |
| AR (1) | AR102096A1 (enExample) |
| AU (4) | AU2015380381B2 (enExample) |
| BR (1) | BR112016023736A2 (enExample) |
| CA (2) | CA2965890A1 (enExample) |
| CL (1) | CL2016002607A1 (enExample) |
| CY (1) | CY1118826T1 (enExample) |
| DK (1) | DK3050556T3 (enExample) |
| EA (3) | EA028484B1 (enExample) |
| ES (1) | ES2584190T3 (enExample) |
| HR (1) | HRP20170625T1 (enExample) |
| HU (1) | HUE034059T2 (enExample) |
| IL (3) | IL247851A0 (enExample) |
| LT (1) | LT3050556T (enExample) |
| ME (1) | ME02721B (enExample) |
| MX (1) | MX352734B (enExample) |
| PE (1) | PE20170296A1 (enExample) |
| PL (1) | PL3050556T3 (enExample) |
| PT (1) | PT3050556T (enExample) |
| RS (1) | RS55959B1 (enExample) |
| RU (1) | RU2669769C2 (enExample) |
| SI (1) | SI3050556T1 (enExample) |
| SM (1) | SMT201700227T1 (enExample) |
| UA (1) | UA116060C2 (enExample) |
| WO (1) | WO2016122722A1 (enExample) |
| ZA (1) | ZA201606903B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| WO2012051106A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| US12370233B2 (en) | 2016-08-31 | 2025-07-29 | Mapi Pharma Ltd. | Depot systems comprising glatiramer acetate |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| KR20240096769A (ko) | 2017-06-29 | 2024-06-26 | 리제너론 파아마슈티컬스, 인크. | 약물 용기를 과충진하기 위한 디바이스 및 방법 |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| EP0693946B1 (en) | 1993-03-24 | 2001-05-16 | Owen Mumford Limited | Improvements relating to injection devices |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP1115743B1 (en) | 1998-09-25 | 2009-05-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| CA2355400A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| AU3846901A (en) | 2000-02-18 | 2001-08-27 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU2001275280B2 (en) | 2000-06-05 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| AU2002353059B2 (en) | 2001-12-04 | 2008-06-19 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| DK1592384T3 (da) | 2003-01-21 | 2012-12-17 | Yeda Res & Dev | Cop 1 til behandling af inflammatoriske tarmsygdomme |
| WO2004091573A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| PL1638589T3 (pl) | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
| US8075919B2 (en) | 2003-07-18 | 2011-12-13 | Baxter International Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| AU2004285553B2 (en) | 2003-10-31 | 2009-12-10 | Teva Pharmaceutical Industries, Ltd. | Nanoparticles for drug delivery |
| EP1701971A2 (en) | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| WO2005084377A2 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| US7495072B2 (en) | 2004-09-09 | 2009-02-24 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| EP1797109B1 (en) | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| JP5297653B2 (ja) | 2004-10-29 | 2013-09-25 | サンド・アクチエンゲゼルシヤフト | グラチラマーの製造法 |
| RU2419638C2 (ru) | 2005-02-02 | 2011-05-27 | Тева Фармасьютикал Индастриз, Лтд. | Способ получения полипептидных смесей с использованием гидрогенолиза |
| CA2596664A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| WO2006116602A2 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| AU2007269140A1 (en) | 2006-07-05 | 2008-01-10 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| US8753833B2 (en) | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| CA2705046C (en) | 2007-07-31 | 2015-03-03 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| EP2111105A4 (en) | 2007-11-28 | 2011-05-04 | METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS | |
| RU2469726C2 (ru) | 2008-05-14 | 2012-12-20 | Отономи, Инк. | Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| KR20140061559A (ko) | 2009-08-20 | 2014-05-21 | 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 | 글라티라머 아세테이트를 포함하는 약제 |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| WO2012051106A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| CA2827275A1 (en) | 2011-02-14 | 2012-09-20 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| CN104902974B (zh) * | 2012-07-06 | 2017-07-28 | 三维矩阵有限公司 | 肽溶液的灌装加工法 |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| EP2941274A4 (en) | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| AU2014248524A1 (en) | 2013-03-12 | 2015-10-29 | Teva Pharmaceutical Industries Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active Active
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active Active
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en active Active
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en not_active Ceased
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 SM SM20170227T patent/SMT201700227T1/it unknown
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es not_active Application Discontinuation
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170296A1 (es) | Procedimiento para fabricar un producto de acetato de glatiramer | |
| AR113782A1 (es) | Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento | |
| WO2017163132A3 (en) | Use of umbilical cord blood derived exosomes for tissue repair | |
| WO2015095624A3 (en) | Drug mixing and delivery system and method | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| HRP20210699T1 (hr) | Izmijenjeni kolagen | |
| EA032938B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| MX2017000764A (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2017507145A5 (enExample) | ||
| MX2018003962A (es) | Proceso para producir fosfinatos. | |
| EP3295932A3 (en) | Stable odf composition containing hardly soluble therapeutic agent | |
| PH12017501828A1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| MX2017008330A (es) | Productos para el suministro de compuestos de diagnóstico/terapeuticos al corazon. | |
| WO2016081296A3 (en) | Topical medicament for skin and mucosal injuries associated with epidermolisis bullosa | |
| MX2016002139A (es) | Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo. | |
| MY187125A (en) | Hydrogel formulation for wound healing and/or treatment | |
| RU2019115423A (ru) | Способ лечения острой ишемии конечностей | |
| WU | Effect of blood pressure variability in patients with hypertension treated by amlodipine combined with perindopril | |
| LIU et al. | Clinical observation on the application of terbinafine and mizolastine in combined treatment of chronic ec-zema with dermatophytes infection | |
| EA201600331A1 (ru) | Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения | |
| LAI et al. | Clinical Observation of Qili San in the Treatment of Trauma-induced Swelling and Pain | |
| UA64380U (ru) | Способ упаковки грецких орехов |